Last reviewed · How we verify

NCT05627076

Analytical Validation of the abioSCOPE Device With the IVD CAPSULE PSP Test: Comparison of PSP Values Measured With Venous Whole Blood and Those Measured With Arterial Whole Blood.

Completed Last updated 25 November 2022
What this trial tests

trial testing Blood Sampling in Sepsis in 46 participants. Completed in 31 October 2022.

Timeline
29 August 2022
Primary endpoint
11 October 2022
31 October 2022

Quick facts

Lead sponsorAbionic SA
StatusCompleted
Study typeOBSERVATIONAL
Enrollment46
Start date29 August 2022
Primary completion11 October 2022
Estimated completion31 October 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Abionic SA

Who can join

18 and older, any sex, with Sepsis or Sepsis Bacterial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Abionic has developed a targeted, rapid test for pancreatic stone protein (PSP) in human K2-EDTA venous whole blood using the abioSCOPE instrument. Currently no PSP study comparaison has been done between venous and arterial whole blood. Abionic would like to confirm the equivalence of the PSP between venous whole blood and arterial whole blood.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood Sampling

Trials testing the same drug.

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other Abionic SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05627076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing